News - Page 2

October 27, 2023

The Santé Active Edition arm of the Santé Active Edition – Synergy Pharm health communication agency has been specializing in medical and scientific communication for professionals (researchers, physicians, veterinarians, pharmacists, etc.), patients, and the general public since 1998.

September 29, 2023

Pink October is the month-long annual campaign dedicated to raising awareness of breast cancer. As happens every year, Pink October 2023 will be marked by a large number of events organized to raise funds for medical and scientific research and increase awareness of the importance of early detection of breast cancer. In France, The Ruban Rose association is organizing an unprecedented event on Sunday the 1^st of October on the Champs-Élysées for the launch of the 2023 Pink October campaign. In the UK, Breast Cancer UK is encouraging everyone to get active with a 30-day challenge to reduce the risk of developing breast cancer and raise money to support breast cancer prevention. In the US, the focus of the National Breast Cancer Foundation is on ensuring Pink October does “more than raise awareness” and promotes action on fundraising and screening.

July 4, 2023

The Synergy Pharm arm of the Santé Active Edition – Synergy Pharm health communication agency has been meeting the regulatory medical writing needs of the pharmaceutical and cosmetics industries, biotech companies, manufacturers of medical devices, healthcare professionals, and the wider scientific research community for more than 30 years.

Synergy Pharm is also a member of France Biotech, and has obtained the Research Tax Credit (“Crédit Impôt Recherche”; CIR) accreditation in France as a service provider performing research and development (R&D) work on behalf of clients eligible for the CIR.

June 14, 2023

Today is MedComms Day!

MedComms Day 2023 is special for us because this year marks the 20th anniversary of Marielle Romet taking over as the head of Santé Active Edition, parent company of the Santé Active Edition – Synergy Pharm group, specializing in medical and scientific writing.

May 16, 2023

Skin cancer (or cutaneous cancer) is one of the most preventable types of cancer because the risk factors are well established. In addition, its onset and development are usually visible at an early stage, and it can be detected by self-examination. However, the global worldwide incidence of skin cancer continues to rise. Campaigns have therefore been implemented to raise awareness among the general population and better prevent this type of cancer.

April 7, 2023

World Health Day is celebrated every year on April, 7. In 2023, this date also marks the 75th anniversary of the World Health Organization (WHO). This is an opportunity to look back at the history of the WHO and advances in public health, and to talk about the contribution of our medical writing agency to some of these programs.

March 13, 2023

The 25^th edition of La Semaine du Cerveau (Brain Awareness Week) is taking place this week (13^th to 19^th of March 2023), providing an opportunity to learn more about the brain and discover recent advances in neuroscience research.

February 27, 2023

If you follow our news, you know that rare diseases are one of the areas of expertise of our medical writing team.

At Santé Active Edition – Synergy Pharm, we are therefore particularly keen to express our support to patients and all those involved in the fight against rare diseases on Rare Disease Day.

February 10, 2023

What is epilepsy?

Epilepsy is a neurological disease affecting approximately 50 million people worldwide. It affects both men and women, regardless of race, ethnicity and age.

January 27, 2023

Research and drug development for rare diseases are often hampered by the need for large numbers of patients to assess clinical trial outcomes and, in the case of rare neurodegenerative diseases, by slow disease progression. In particular, the “by eye” behavioral assessments currently used to monitor disease progression require long-term observation to detect changes in patient status, may be subject to observer bias, and can lack the precision needed to detect small but clinically relevant alterations in functional capabilities.